Mark Kirschbaum

List of Publications by Year
in descending order

28 papers	1,104 citations	759233 12 h-index	677142 22 g-index
28 all docs	28 docs citations	28 times ranked	2013 citing authors

#	Article	IF	Citations
1	Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clinical Cancer Research, 2016, 22, 868-876.	7.0	262
2	Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. Journal of Clinical Oncology, 2011, 29, 1198-1203.	1.6	195
3	The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Phâ˜ acute lymphoblastic leukemia cells. Blood, 2008, 111, 5093-5100.	1.4	134
4	Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood, 2007, 109, 905-909.	1.4	116
5	A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. British Journal of Haematology, 2014, 167, 185-193.	2.5	115
6	HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4796-4801.	7.1	90
7	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica, 2015, 100, 357-362.	3.5	66
8	Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.. Blood, 2006, 108, 2165-2165.	1.4	19
9	A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL). Blood, 2010, 116, 657-657.	1.4	16
10	Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood, 2008, 112, 1567-1567.	1.4	12
11	Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).. Blood, 2009, 114, 1657-1657.	1.4	12
12	Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study.. Blood, 2009, 114, 2089-2089.	1.4	12
13	Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia. Blood, 2012, 120, 675-675.	1.4	12
14	A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells. Anticancer Research, 2007, 27, 3783-9.	1.1	12
15	Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).. Blood, 2008, 112, 1568-1568.	1.4	10
16	Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Blood, 2008, 112, 3651-3651.	1.4	6
17	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkinâ€™s Lymphoma. A California Cancer Consortium Study.. Blood, 2008, 112, 1564-1564.	1.4	5
18	Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.. Blood, 2009, 114, 1708-1708.	1.4	3

#	Article	IF	Citations
19	Peripheral Blood Stem Cells vs Bone Marrow for Matched Sibling Transplant in AML and ALL in First Remission.. Blood, 2004, 104, 3321-3321.	1.4	2
20	A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.. Blood, 2006, 108, 1948-1948.	1.4	2
21	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Blood, 2010, 116, 3957-3957.	1.4	2
22	hENT1 and Hodgkin lymphoma: Not just crossing the channel. Leukemia and Lymphoma, 2008, 49, 1024-1025.	1.3	1
23	Comeback for the camptothecins?. Leukemia and Lymphoma, 2009, 50, 1914-1915.	1.3	0
24	Risk Adapted BEACOPP Regimen Based on Early Scintigraphy Can Reduce the Cumulative Dose of Chemotherapy for Standard and High Risk Hodgkin Lymphoma (HD) with No Impairment of Outcome.. Blood, 2005, 106, 815-815.	1.4	0
25	Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs. Blood, 2008, 112, 3628-3628.	1.4	0
26	Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.. Blood, 2009, 114, 1682-1682.	1.4	0
27	Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.. Blood, 2009, 114, 1690-1690.	1.4	0
28	Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Phâ˜ Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589... Blood, 2009, 114, 3083-3083.	1.4	0